UNIVERSITY research incubator Fusion IP said one of its spin-outs is collaborating on a new European Union research project to treat hormone deficiency in infants.
Sheffield-based Fusion said its Cardiff University spin-out Diurnal has been announced as a major partner on the Treatment of Adrenal Insufficiency in Neonates (TAIN) programme. The project is also supported by the Welsh Assembly Government.
The programme aims to create an approved version of hydrocortisone for children for the first time, specifically for babies and infants who suffer from adrenal insufficiency.
“This is a prestigious award for Diurnal who will be taking a leading role in this project,” said Fusion IP operations director Peter Grant. “With potentially over 1.6m euros in EU contribution being allocated to Diurnal over the timeframe of the project, successful completion of the TAIN project will highlight Diurnal’s capabilities in orphan drug development.”
Fusion has exclusive rights to commercialise research from Sheffield and Cardiff universities.